Cheap drug protects against contrast-induced nephropathy

Article

As the number of patients undergoing contrast-enhanced CT scans grows, so does the risk of contrast-induced nephropathy. How to protect patients? By asking them to pop an N-acetylcysteine (NAC) pill before the exam.

Principal investigator Dr. Aine M. Kelly and colleagues at the University of Michigan Medical School analyzed data from 41 studies that evaluated several kidney-protecting drugs. They found that patients who took NAC could avoid serious kidney damage caused by iodine-based contrast agents. The drug costs about 25¢ for a 500 mg dose and is available in most pharmacies. The investigators also found NAC outperforms other medicines used for the same purpose. Findings were published in the Feb. 19 issue of the Annals of Internal Medicine.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.